SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001664710-21-000057
Filing Date
2021-09-09
Accepted
2021-09-09 16:02:37
Documents
12
Period of Report
2021-09-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K kros-20210907.htm   iXBRL 8-K 45898
  Complete submission text file 0001664710-21-000057.txt   197924

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20210907.xsd EX-101.SCH 1899
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20210907_lab.xml EX-101.LAB 26869
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20210907_pre.xml EX-101.PRE 14117
5 EXTRACTED XBRL INSTANCE DOCUMENT kros-20210907_htm.xml XML 13144
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39264 | Film No.: 211244423
SIC: 2834 Pharmaceutical Preparations